Morgan Stanley sets a Buy rating for BioNTech stock
Published on 10/06/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioNTech SE (ISIN US09075V1026) was trading at EUR 88.08 at Lang & Schwarz on October 6, 2026 at 1:49 p.m. CEST, up 1.26 percent versus the prior close of EUR 86.98. On October 5, 2026, Morgan Stanley analyst Terence Flynn assigned a Buy rating to BioNTech and set a USD 115.00 price target, as Markets Insider reported.
Morgan Stanley sets a new marker
The new rating gives BioNTech's oncology transition a fresh valuation reference in US dollars, while the euro quote provides the relevant view for investors trading in Germany. The USD 115.00 target is separate from the EUR 88.08 Lang & Schwarz price and cannot be converted into a target distance without mixing currencies.
The analyst action follows a difficult earnings backdrop. MarketBeat reported that 12 of 19 covering brokerages rated the stock Buy or Strong Buy, while five rated it Hold and one rated it Sell. The same overview put the average 12-month target at USD 126.00.
Oncology data add a counterweight
BioNTech's product pipeline supplies a second valuation anchor. In data published on September 14, 2026, BioNTech said gotistobart produced median overall survival of 18.5 months in stage one of the PRESERVE-003 trial, compared with 10.0 months for docetaxel.
The comparison covered 87 patients and carried a hazard ratio of 0.56, but the pivotal stage two portion remains ongoing at more than 160 sites. That distinction matters: the current figure is an interim clinical signal, not a commercial approval or a completed pivotal readout.
EUR quote gains 1.26 percent
BioNTech's Nasdaq-listed ADR was last at USD 97.64 on October 5, 2026 at 4:00 p.m. ET. The stock's USD 24.5 billion market capitalization and USD 79.52 to USD 124.00 52-week range frame the current valuation, while the Lang & Schwarz quote shows the German-market reaction in euros.
The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.
BioNTech stock at a glance
- Company: BioNTech SE
- ISIN: US09075V1026
- Ticker: BNTX
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 6, 2026 at 1:49 p.m. CEST: EUR 88.08
- Change versus prior close: plus 1.26 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 86.98
- Market capitalization: USD 24.5 billion (as of October 5, 2026)
- 52-week range: USD 79.52-USD 124.00 (as of October 5, 2026)
- Sector / Industry: Healthcare / Biotechnology
